Download Is the world`s 3rd largest pharmaceutical market ready for

Is the world’s 3rd largest pharmaceutical market ready for
patient-centric clinical trials?
Saumya Nayak
Manager, Site and Patient Networks (SPN)
Quintiles
1
Disclaimer
The views and opinions expressed in the following PowerPoint slides
are those of the individual presenter and should not be attributed to
Drug Information Association, Inc. (“DIA”), its directors, officers,
employees, volunteers, members, chapters, councils, Communities or
affiliates, or any organization with which the presenter is employed or
affiliated.
These PowerPoint slides are the intellectual property of the individual
presenter and are protected under the copyright laws of the United
States of America and other countries. Used by permission. All rights
reserved. Drug Information Association, Drug Information Association
Inc., DIA and DIA logo are registered trademarks. All other trademarks
are the property of their respective owners.
2
Adopting Patient-Centric Clinical Trial Model
Patient-centricity in a clinical trial means designing & conducting
a study in a way that is responsive to patient preferences, needs
and values
HOW
BENEFITS
Addresses key challenges By engaging patient groups to gather patients’ feedback
of conducting clinical trials
Developing Trust
Protocol amendments
Enrolment delay
Patient retention
3
Maintaining Transparency
Engaging
Patient
Groups
Patient Engagement
Frequent Communication
Patient Advocacy / Support Groups’ Landscape in China
The objective of current research was to gain a better
understanding of patient advocacy and/or support groups’ current
landscape in China; mainly, their size, structure, experience and
interest in driving patient-centric clinical trials.
4
Patient Advocacy / Support Groups’ Landscape in China
PATIENT-CENTRIC activities that are of interest to more than 70% of groups
73%
Small-sized groups
Sharing
information on
specific clinical trials
83%
Medium-sized groups
•
Referring patients and
•
Sharing information on
specific clinical trials
• Connecting patients with biopharmaceutical companies
to uncover patient insights
80-100%
Large-sized groups
• Referring patients to clinical trial sites
• Sharing information on specific clinical trials
• Participating in round table consortiums to give
feedback on trial protocols and outcome
5
Conducting Patient-Centric Clinical Trials in China
There are hundreds of patient groups in China varying in size,
structure and interest.
Creating a ‘heat map’ of patient groups is beneficial for biopharmaceutical companies as different groups may prove more
valuable collaborators at different stages of the clinical trial
based on their interest.
Patient groups in China are willing to broaden their horizon by
adopting patient-centric activities, thus offering yet another
benefit of conducting patient-centric trials
6
Thank You
Saumya Nayak
Manager, Patient and Site Services
Quintiles
Join the conversation #DIA2016
7